A Phase 2 Study of Obinutuzumab, Sonrotoclax, and Zanubrutinib in People With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Full Title

A Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Purpose

Researchers want to see how well the combination of obinutuzumab, sonrotoclax, and zanubrutinib works against leukemia and lymphoma. The people in this study have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has not been treated.

• Obinutuzumab blocks a protein that can cause tumors to grow. It is a standard treatment for your type of cancer.
• Sonrotoclax is a BCL-2 inhibitor. These drugs block proteins on cancer cells that play a role in cancer growth and survival. By blocking these proteins, sonrotoclax may help slow or stop the growth of your cancer.
• Zanubrutinib blocks a protein called BTK. It is a standard treatment for your type of cancer.

The researchers think that combining obinutuzumab, sonrotoclax, and zanubrutinib may work better against cancer than any of the drugs given alone. Zanubrutinib is taken orally, while the other drugs are given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Be newly diagnosed with CLL or SLL.
• Have not yet received treatment for CLL or SLL.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information about this study or to see if you can join, please call Dr. Andrew Zelenetz’s office at 646-608-3728.